USA - engelsk - NLM (National Library of Medicine)

butler animal health supply, llc, d/b/a/ henry schein animal health - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 3 mg in 1 ml - indications and usage: dexaject sp is indicated as a rapid adrenal glucocorticoid and/or anti-inflammatory agent in horses. contraindications : do not use in viral infections. except when used for emergency therapy, dexamethasone sodium phosphate is contraindicated in animals with tuberculosis and chronic nephritis. existence of congestive heart failure, osteoporosis and diabetes are relative contraindications. in the presence of infection appropriate antibacterial agents should also be administered and should be continued for at least 3 days after discontinuance of the hormone and disappearance of all signs of infection.

USA - engelsk - NLM (National Library of Medicine)

bimeda, inc. - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 3 mg in 1 ml - indications and usage: dexamethasone sodium phosphate injection is indicated as a rapid adrenal glucocorticoid and/or anti-inflammatory agent in horses. contraindications: do not use in viral infections. except when used for emergency therapy, dexamethasone sodium phosphate is contraindicated in animals with tuberculosis and chronic nephritis. existence of congestive heart failure, osteoporosis and diabetes are relative contraindications. in the presence of infection appropriate antibacterial agents should also be administered and should be continued for at least 3 days after discontinuance of the hormone and disappearance of all signs of infection.

Israel - engelsk - Ministry of Health

mbi pharma ltd., israel - dexamethasone as sodium phosphate - solution for injection - dexamethasone as sodium phosphate 4 mg/ml - dexamethasone - dexamethasone kern pharma is indicated in the treatment of:• endocrine diseases such as nonsuppurative thyroiditis, hypercalcaemia associated with cancer and congenital adrenal hyperplasia.• allergy: severe or disabling allergic conditions resistant to conventional treatments, as in: bronchial asthma, contact or atopical dermatitis, seasonal or perennial allergic rhinitis, hypersensitivity reactions to drugs.• ophtalmic: serious inflammatory and allergic processes, acute and chronic, affecting the eyes, such as: iritis and iridocyclitis, chorioretinitis, choroiditis and diffuse posterior uveitis, optical neuritis, allergic conjunctivitis, allergic marginal corneal ulcers.• inflammatory bowel dis.: systemic treatment in exacerbations of ulcerative colitis and regional enteritis.• dermatological diseases (pemphigus, stevens johnson syndrome, exfoliative dermatitis, severe psoriasis and mycosis fungoides) • respiratory diseases (symptomatic sarcoidosis, berylliosis, loeffler's syndrome)• haematologica

Irland - engelsk - HPRA (Health Products Regulatory Authority)

perrigo pharma international designated activity company - dexamethasone sodium phosphate - oral solution - 10 mg/5ml - glucocorticoids; dexamethasone

Irland - engelsk - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - dexamethasone sodium phosphate - solution for injection - 4 milligram(s)/millilitre - dexamethasone

Irland - engelsk - HPRA (Health Products Regulatory Authority)

rosemont pharmaceuticals ltd - dexamethasone sodium phosphate - oral solution - 10 mg/5ml - glucocorticoids; dexamethasone

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

multichem nz limited - dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml - solution for injection - 4 mg/ml - active: dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml excipient: citric acid monohydrate creatinin sodium citrate sodium hydroxide water for injection - replacement therapy - adrenocortical insufficiency dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy. it should be supplemented with salt and or a mineralocorticoid. when so supplemented dexamethasone is indicated in: · acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy. relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available. primary and secondary adrenocortical insufficiency.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

multichem nz limited - dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml - solution for injection - 8 mg/2ml - active: dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml excipient: citric acid monohydrate creatinin sodium citrate sodium hydroxide water for injection - replacement therapy - adrenocortical insufficiency dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy. it should be supplemented with salt and or a mineralocorticoid. when so supplemented dexamethasone is indicated in: · acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy. relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available. primary and secondary adrenocortical insufficiency.

USA - engelsk - NLM (National Library of Medicine)

stat rx usa - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - for the treatment of the following conditions:  steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies.  steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. epithelial herpes simplex keratitis (dendritic keratitis). acute infectious stages of vaccinia, varicella and many other viral diseases of the cornea and conjunctiva. mycobacterial infection of the eye. fungal diseas

USA - engelsk - NLM (National Library of Medicine)

phoenix pharmaceutical, inc. - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - for the treatment of the following conditions: ophthalmic: steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. otic: steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. epithelial herpes simplex keratitis (dendritic keratitis). acute infectious stages of vaccinia, varicella and many other viral diseases of the cornea and conjunctiva. mycobacterial infection of the eye. funga